Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 33 (1), 21-5

Effects of Depression and Serotonergic Antidepressants on Bone: Mechanisms and Implications for the Treatment of Depression

Affiliations
Review

Effects of Depression and Serotonergic Antidepressants on Bone: Mechanisms and Implications for the Treatment of Depression

Brisa S Fernandes et al. Drugs Aging.

Abstract

Osteoporosis is a chronic skeletal disease marked by microarchitectural deterioration of the bone matrix and depletion of bone mineral density (BMD), with a consequent increased risk for fragility fractures. It has been frequently associated with depression, which is also a chronic and debilitating disorder with high prevalence. Selective serotonin reuptake inhibitors (SSRIs), first-line agents in the pharmacological treatment of mood and anxiety disorders, have also been shown to negatively affect bone metabolism. SSRIs are the most prescribed antidepressants worldwide and a large number of persons at risk of developing osteoporosis, including older patients, will receive these antidepressants. Therefore, a proper musculoskeletal evaluation of individuals who are being targeted for or using SSRIs is a priority. The aim of this article is to review the evidence regarding the effects of depression and serotonergic antidepressants on bone and its implications for clinical care.

Similar articles

See all similar articles

Cited by 13 PubMed Central articles

See all "Cited by" articles

References

    1. Biol Psychiatry. 2009 Sep 1;66(5):423-32 - PubMed
    1. Hormones (Athens). 2013 Jul-Sep;12(3):350-62 - PubMed
    1. Nat Med. 2011 Jun;17(6):684-91 - PubMed
    1. J Am Med Dir Assoc. 2012 Jun;13(5):413-7 - PubMed
    1. Bone. 2001 Nov;29(5):477-86 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback